deepc, a company behind the leading AI operating system for radiologists and enterprise clinical organizations, announced the closure of its Series A with a €12 million extension round, bringing the company’s total funding to date to €27.6 million. The funding was co-led by Sofinnova Partners and Bertelsmann Investments, with participation from new investors KHP Ventures and SwissHealth Ventures, alongside existing investor Winning Mindset Ventures.
The funding will be used to accelerate deepc’s growth and international expansion, as well as further enhance and commercialize its industry-leading operating system. Key priorities for growth include extending deepc’s presence in the United States, further expanding in the United Kingdom and doubling down on key European markets.
Today, deepc’s platform is used by leading organizations including Solothurn Hospital in Switzerland, the Vivantes Hospital Group and LMU University Hospital in Germany, CHU Brugmann (Brugmann University Hospital) in Belgium, as well as the National Health Service (NHS) in England.
Dr. Franz Pfister, CEO and Co-Founder of deepc, said: “At deepc, we believe that the potential for AI in healthcare will only be realized if we can bridge the gap between cutting-edge AI and clinical practice. Our platform makes it easy for organizations to adopt the best AI technologies at pace and at scale, enabling faster, more accurate diagnoses and ultimately improving patient outcomes. We are thrilled to welcome SwissHealth Ventures and KHP Ventures, alongside our existing investors Sofinnova Partners, Bertelsmann Investments, and Winning Mindset Ventures. Together, they bring tremendous strategic value to deepc and will be a major asset as we continue to scale internationally and invest further in our platform.”
Founded in 2019, deepc is driven by a vision to help ensure precise and safe diagnostics for all patients and has a strong track record of helping radiology AI providers deploy their technologies in clinical settings through a single integration solution.
Through deepcOS®, clinicians can access regulatory-approved AI solutions for more than 60 clinical indications, allowing healthcare providers to benefit from the rapid developments taking place within radiology AI without any of the technical, operational, or commercial complexity. By giving AI developers low-friction access to deepc’s broad customer base and distribution network spanning over 30 countries, deepc is also helping accelerate the development of new AI solutions.
Simon Turner, Partner at Sofinnova Partners, added: “The influx of capital into AI is highlighting the importance of enabling technologies that drive adoption in healthcare. These enabling technologies are the focus of the Sofinnova Digital Medicine strategy, and an area that few have yet to command. From the outset, we recognized deepc’s potential to revolutionize AI deployment in healthcare. This conviction is reinforced today by the support of our new investors who bring a wealth of expertise to further accelerate the company’s growth.”